Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Next Previous
Search
Trial Profile

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Carboplatin; Cisplatin; Corticosteroids; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Fludarabine; Gemcitabine; Ifosfamide; Methylprednisolone; Oxaliplatin
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ZUMA-7
  • Sponsors Kite Pharma

    • Most Recent Events

    • 24 Dec 2024 Status changed from active, no longer recruiting to completed.
    • 08 Dec 2024 According to Kite Media release,Real-World Evidence (RWE) Analysis of Yescarta from this study presented at 66th American Society of Hematology (ASH) Annual Meeting & Exposition..
    • 08 Dec 2024 Results published in the Kite Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top